ReviewFrontiers in immunology2026
Regulatory T cells in bullous pemphigoid: biological characteristics, dysfunction, and pathogenic roles.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. Its pathogenesis involves the disruption of the basement membrane zone (BMZ), driven by pathogenic autoantibodies and a pronounced inflammatory response. Current first-line therapies, primarily based on glucocorticoids and immunosuppressants, are limited by substantial side effects and frequent disease recurrence. Regulatory T cells (Tregs) play a central role in maintaining immune homeostasis and peripheral tolerance, exerting control over effector immune cells through transcriptional regulation, surface markers, and diverse immunosuppressive mechanisms. Accumulating evidence indicates that numerical reduction and functional impairment of Tregs are critical to the breakdown of immune tolerance in BP. Treg dysfunction leads to the aberrant activation of Th2, Th17, and follicular helper T (Tfh) cells, which in turn promotes the production of anti-BP180/BP230 autoantibodies and disrupts the regulation of inflammatory cells such as neutrophils and eosinophils. These events collectively result in BMZ degradation and blister formation. Multiple factors, including age-related immunosenescence, genetic predisposition, pharmacological exposures, and environmental stimuli, can further compromise Treg function, thereby contributing to BP pathogenesis. A deeper understanding of Treg-driven mechanisms in BP provides a rational basis for developing targeted therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.